businesspress24.com - DGAP-News: Cytos Biotechnology Ltd announces full year 2011 financial results
 

DGAP-News: Cytos Biotechnology Ltd announces full year 2011 financial results

ID: 1084173

(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Final
Results
Cytos Biotechnology Ltd announces full year 2011 financial results

17.02.2012 / 07:00

---------------------------------------------------------------------

Schlieren (Zurich), Switzerland, February 17, 2012 - Cytos Biotechnology
Ltd (SIX:CYTN) today presented its full year 2011 financial results.

The complete press release as well as the Annual Report 2011 can be
downloaded on Cytos Biotechnology's website (www.cytos.com).

For further information please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel.: +41 44 733 46 46
e-Mail: harry.welten(at)cytos.com
Website: www.cytos.com

About Cytos Biotechnology Ltd
Cytos Biotechnology Ltd is a Swiss public biotechnology company that
specializes in the development and commercialization of a new class of
biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM) are
intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. The Immunodrug(TM) candidates are developed both in-house and
together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as
a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich,
the Company is located in Schlieren (Zurich). Cytos Biotechnology Ltd is
listed on the main segment at the SIX Swiss Exchange (SIX:'CYTN').


End of Corporate News

---------------------------------------------------------------------

17.02.2012 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the




capital market and press releases.
The EquityStory Group distributes authentic and real-time financial
news for over 1'300 listed companies.
The Swiss news archive can be found at
http://www.equitystory.ch/nachrichten


---------------------------------------------------------------------


Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart;
Open Market in Frankfurt; SIX


End of News EquityStory AG News-Service
---------------------------------------------------------------------
157148 17.02.2012


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  DGAP-News: SINGULUS TECHNOLOGIES AG: SINGULUS TECHNOLOGIES Receives New Order for Thin-Film Solar Technology
DGAP-News: Nemetschek AG: Nemetschek enjoys renewed growth of 10 percent
Bereitgestellt von Benutzer: EquityStory
Datum: 17.02.2012 - 01:00 Uhr
Sprache: Deutsch
News-ID 1084173
Anzahl Zeichen: 0

contact information:
Contact person:
Town:


Phone:

Kategorie:

Business News


Anmerkungen:


Diese Pressemitteilung wurde bisher 79 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos Biotechnology Ltd announces full year 2011 financial results
"
steht unter der journalistisch-redaktionellen Verantwortung von

Cytos Biotechnology AG (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Cytos Biotechnology AG



 

Who is online

All members: 10 590
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 603


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.